BCL2 and ovarian carcinoma: Based on the reliability of urinary levels of Bcl-2 as a biomarker for detecting ovarian cancer at early stages and distinguishing cancer from other gynecological conditions [4], the development of an ultrasonic biosensor has been undertaken to ultimately be used for point-of-care diagnosis.